Allevi Press

Allevi Inc. and the Wistar Institute Collaborate on 3D Bioprinting Project to Advance COVID-19 Research

Allevi 3D bioprinted lung models will be used to study SARS-CoV-2 mechanisms of disease progression

PHILADELPHIA — (June 25th, 2020) — The Wistar Institute, a biomedical research leader in cancer, immunology and infectious diseases, and Allevi, Inc. a Philadelphia based startup pioneering innovative 3D biofabrication technologies, announce a collaboration to use 3D bioprinting to help combat COVID-19.

In a time where the coronavirus pandemic has led to nearly 8 million infections and more than 437,000 deaths worldwide1, scientific research is more important than ever. Allevi will apply its patented 3D bioprinting platform to create three-dimensional lung models that Wistar scientists will use to study SARS-CoV-2, the virus that causes COVID-19. The goal will be to investigate the mechanisms deployed by this pathogen to infect humans and identify potential ways in which it may be blocked.

Wistar expertise in immunology and virology and its state-of-the-art biosafety level 3 capabilities to safely study pathogens combined with Allevi’s platform technology will be essential to the success of this collaboration.

“We are accompanying the spectacular work from our peers in the scientific community and have identified tremendous potential for our platform to enable COVID-19 research in a much faster, yet physiologically relevant manner,” said Taciana Pereira, Allevi Vice President of Life Sciences and a co-principal investigator on the project. “We believe that scientists from all areas need to unite now to solve this crisis, so we are ecstatic to work with Wistar and Dr. David Weiner.”

The collaboration will be led by David B. Weiner, Ph.D., Executive Vice President, Director of the Vaccine & Immunotherapy Center (VIC), and W.W. Smith Charitable Trust Professor in Cancer Research. “We have been advancing scientific investigations aimed at the treatment and prevention of COVID-19, and we believe that Allevi’s innovative approach is an exciting modality to gain unique insights into the inner workings of the novel coronavirus,” stated Weiner, also a co-principal investigator on the project.

“This project has the potential to be a significant asset in the fight against COVID-19, and the scientific community will benefit greatly from this endeavor,” said Robert Langer, Sc.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) and Allevi Scientific Advisory Board member.

(1) Data from the Johns Hopkins University Center for Systems Science and Engineering (Updated June 16, 2020)

Founded in 2014, Allevi’s mission is to make it easy to design and engineer 3D tissues using desktop 3D bioprinters that are versatile, powerful, and easy-to-use. Allevi’s 3D bioprinters and bioinks are trusted by leading researchers and industry giants in hundreds of labs globally in the fields of tissue engineering, organ-on-a-chip research, pharmaceutical validation, biomaterial development, and regenerative medicine.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. Wistar’s Business Development team is dedicated to advancing Wistar Science and Technology Development through creative collaborations.

Share this post